(11) **EP 1 312 366 A8**

(12)

CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC Note: Bibliography reflects the latest situation

- (15) Correction information:

 Corrected version no 1 (W1 A1)

 INID code(s) 71
- (48) Corrigendum issued on: **12.11.2003 Bulletin 2003/46**
- (43) Date of publication: **21.05.2003 Bulletin 2003/21**
- (21) Application number: 01956809.6
- (22) Date of filing: 08.08.2001

- (51) Int Cl.⁷: **A61K 31/5383**, A61K 9/08, A61K 47/12, A61K 47/34, A61K 47/38, A61P 31/04
- (86) International application number: **PCT/JP01/06805**
- (87) International publication number: WO 02/011734 (14.02.2002 Gazette 2002/07)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:

AL LT LV MK RO SI

- (30) Priority: 08.08.2000 JP 2000240455
- (71) Applicant: Wakamoto Pharmaceutical Co., Ltd. Chuo-ku, Tokyo 103-8330 (JP)
- (72) Inventors:
 - SUZUKI, Hidekazu, c/o WAKAMOTO PHARM. CO., LTD. Chuo-ku, Tokyo 103-8330 (JP)

- WADA, Takahiro,
 c/o WAKAMOTO PHARM. CO., LTD.
 Chuo-ku, Tokyo 103-8330 (JP)
- KIRITA, Masanobu Kashiwa-shi, Chiba 277-0084 (JP)
- TAKEUCHI, Masanobu, c/o WAKAMOTO PHARM. CO., LTD. Chuo-ku, Tokyo 103-8330 (JP)
- (74) Representative:

(54) AQUEOUS PHARMACEUTICAL COMPOSITIONS

(57) The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration, thereby attaining high availability of a

pharmaceutical agent.

The present invention relates to an antibacterial aqueous pharmaceutical composition

which comprises: 2.8 to 4 w/v% of methylcellulose, the 2 w/v% aqueous solution of which has a viscosity of 12 mPa·s or below at 20°C; 1.5 to 2.3 w/v% of citric acid; 2 to 4 w/v% of polyethylene glycol; and 0.1 to 0.5 w/v% of ofloxacin.